A Study of Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
This single-arm study will assess the efficacy and safety of intravenous (IV) Mircera when
administered for the maintenance of hemoglobin (Hb) levels in participants with chronic renal
anemia. Individuals currently receiving maintenance treatment with epoetin alfa or
darbepoetin alfa will receive monthly injections of Mircera, with the starting dose (120,
200, or 360 micrograms [mcg] IV injection) derived from the dose of epoetin alfa or
darbepoetin alfa they were receiving in the week preceding study start.